Analysis of relationship between OCs use and risk of HER2-positive BrCa (HER2+ BrCa) subtype included eight trials, and was based on data from 12,704 participants (cases: 1063, control: 11,641) [45,48,49,50,54,55,58,61]. The gene discussed is ERBB2; the disease is invasive breast carcinoma.